ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Cetirizine (systemic): Drug information

Cetirizine (systemic): Drug information
(For additional information see "Cetirizine (systemic): Patient drug information" and see "Cetirizine (systemic): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • All Day Allergy [OTC] [DSC];
  • Allergy (Cetirizine) [OTC];
  • Allergy Relief (Cetirizine) [OTC];
  • Allergy Relief Cetirizine [OTC];
  • Allergy Relief Childrens [OTC];
  • Allergy Relief/Indoor/Outdoor [OTC];
  • Cetirizine HCl Allergy Child [OTC];
  • Cetirizine HCl Childrens Alrgy [OTC];
  • Cetirizine HCl Childrens [OTC] [DSC];
  • GoodSense All Day Allergy [OTC];
  • Quzyttir;
  • ZyrTEC Allergy Childrens [OTC];
  • ZyrTEC Allergy [OTC];
  • ZyrTEC Childrens Allergy [OTC];
  • ZyrTEC [OTC]
Brand Names: Canada
  • AG-Cetirizine;
  • APO-Cetirizine;
  • BIO-Cetirizine;
  • JAMP-Cetirizine;
  • M-Cetirizine;
  • Mar-Cetirizine;
  • MINT-Cetirizine;
  • NRA-Cetirizine;
  • PMS-Cetirizine;
  • Priva-Cetirizine [DSC];
  • Reactine;
  • TEVA Cetirizine
Pharmacologic Category
  • Histamine H1 Antagonist;
  • Histamine H1 Antagonist, Second Generation;
  • Piperazine Derivative
Dosing: Adult
Allergic rhinitis or conjunctivitis

Allergic rhinitis or conjunctivitis: Oral: 10 mg once daily; alternatively, may be given as needed 2 to 5 hours before exposure to allergen, although this may be less effective than daily administration (Ref).

OTC labeling (patient-guided therapy for symptoms of hay fever or other upper respiratory allergies): 5 to 10 mg once daily (maximum: 10 mg/day).

Anaphylaxis

Anaphylaxis (adjunct to epinephrine for relief of cutaneous symptoms) (off-label use): Note: Do not use for initial or sole treatment of anaphylaxis because H1 antihistamines do not relieve upper or lower airway obstruction or shock (Ref).

IV, Oral: 10 mg as a single dose (Ref).

Angioedema, acute allergic or recurrent idiopathic

Angioedema, acute allergic or recurrent idiopathic (off-label use): Note: Not indicated for angioedema with anaphylaxis; use epinephrine if anaphylaxis symptoms are present (ie, risk of airway or cardiovascular compromise is present) (Ref).

Oral: 10 mg once or twice daily; may increase up to 20 mg twice daily (Ref).

Infusion reaction, premedication

Infusion reaction, premedication (adjunct) (alternative agent) (off-label use): Note: Used in some protocols as an alternative to a sedating antihistamine (eg, diphenhydramine). An optimal premedication regimen has not been identified; refer to institutional protocols as variations exist (Ref).

Oral: 10 mg typically administered 30 to 60 minutes prior to infusion of certain chemotherapy agents or biologics; may be given with an H2 antihistamine (eg, ranitidine) and/or a glucocorticoid (Ref).

Urticaria, new onset and chronic spontaneous

Urticaria, new onset and chronic spontaneous:

New onset:

Oral (off-label use): Initial: 10 mg once daily. If symptom control is inadequate, may immediately increase to 10 mg twice daily (Ref).

IV: 10 mg once daily as needed.

Chronic spontaneous:

Oral: Initial: 10 mg once daily. If symptom control is inadequate, may increase in increments of 10 mg/day every 1 to 4 weeks up to 20 mg twice daily. Periodically reevaluate necessity for continued treatment (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

IV: No dosage adjustment necessary (formulation only intended for short-term use).

Oral: Note: Renally adjusted dose recommendations are based on usual doses of 5 to 10 mg once daily.

Altered kidney function:

CrCl >31 mL/minute: No dosage adjustment necessary.

CrCl 11 to ≤31 mL/minute: 5 mg once daily.

CrCl ≤10 mL/minute: 5 mg once every 48 hours; may increase to 5 mg once daily based on tolerability and response for short-term use only (drug may accumulate with prolonged use at this dose (Ref)).

Hemodialysis, intermittent (thrice weekly): <10% dialyzable; 5 mg 3 times per week (Ref); may increase to 5 mg once daily based on tolerability and response for short-term use only (drug may accumulate with prolonged use at this dose (Ref)).

Peritoneal dialysis: Unlikely to be significantly dialyzed (Ref): 5 mg once every 48 hours; may increase to 5 mg once daily based on tolerability and response for short-term use only (drug may accumulate with prolonged use at this dose (Ref).

Dosing: Hepatic Impairment: Adult

Mild to severe impairment: 5 mg once daily.

Dosing: Older Adult

Upper respiratory allergies, urticaria: Oral: 5 mg once daily (maximum dose: 5 mg daily). The previously available prescription product recommended a maximum dose of 10 mg once daily in patients <77 years of age or 5 mg once daily in patients ≥77 years of age (Ref).

Dosing: Pediatric

(For additional information see "Cetirizine (systemic): Pediatric drug information")

Allergic rhinitis, perennial

Allergic r hinitis, perennial:

Infants 6 to <12 months: Oral: 2.5 mg once daily.

Children 12 to 23 months: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily.

Allergic symptoms, hay fever

Allergic symptoms, hay fever:

Children 2 to 5 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily or 5 mg once daily; maximum daily dose: 5 mg/day.

Children ≥6 years and Adolescents: Oral: 5 to 10 mg once daily.

Anaphylaxis; adjunctive for cutaneous symptoms

Anaphylaxis; adjunctive for cutaneous symptoms: Limited data available (Ref): Note: Do not use for initial or sole treatment of anaphylaxis; H1 antihistamines are not effective for upper or lower airway obstruction or shock (Ref). If cutaneous symptoms persist, dose may be repeated in 24 hours (see Urticaria, acute dosing).

Infants ≥6 months and Children <2 years: Oral: 2.5 mg once.

Children 2 to 5 years: Oral 2.5 to 5 mg once.

Children >5 years and Adolescents: Oral: 5 to 10 mg once.

Urticaria, acute

Urticaria, acute:

IV:

Infants ≥6 months to Children ≤5 years: 2.5 mg every 24 hours.

Children 6 to 11 years: 5 mg or 10 mg every 24 hours; reserve higher dose for more severe symptoms.

Children ≥12 years and Adolescents: 10 mg every 24 hours.

Oral: Limited data available (Ref):

Infants ≥6 months and Children <2 years: Oral: 2.5 mg once daily.

Children 2 to 5 years: Oral: 2.5 to 5 mg once daily.

Children >5 years and Adolescents: Oral: 5 to 10 mg once daily.

Urticaria, chronic spontaneous

Urticaria, chronic spontaneous: Limited data available in Children >5 years and Adolescents. Note: Considered first-line therapy for management of chronic urticaria; if response inadequate after 2 to 4 weeks of therapy or symptoms intolerable, consider increasing the dose of cetirizine (as age and weight permits) as second-line treatment rather than changing therapy (Ref).

Infants 6 to <12 months: Oral: 2.5 mg once daily.

Infants ≥12 months and Children <2 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily.

Children 2 to 5 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily or 5 mg once daily; maximum daily dose: 5 mg/day.

Children 6 to 11 years: Oral: 5 mg once daily or twice daily (Ref).

Children ≥12 years and Adolescents: Oral: 10 mg once daily (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

IV: Note: Has only been evaluated for acute indications (short-term therapy).

Infants ≥6 months and Children <6 years: Avoid use in patients with any degree of renal impairment; has not been studied.

Children ≥6 years and Adolescents: Moderate to severe impairment; end-stage renal disease on dialysis: No adjustment necessary; monitor for antihistamine side effects and adjust therapy if needed.

Oral: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Ref):

Infants, Children, and Adolescents:

GFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.

GFR 10 to 29 mL/minute/1.73 m2: Decrease dose by 50%.

GFR <10 mL/minute/1.73 m2: Not recommended.

Intermittent hemodialysis or peritoneal dialysis: Decrease dose by 50%.

Dosing: Hepatic Impairment: Pediatric

IV: Note: Has only been evaluated for acute indications (short-term therapy).

Infants ≥6 months to Children <6 years: Avoid use with hepatic impairment; has not been studied.

Children ≥6 years and Adolescents: No dosage adjustment required; monitor for antihistamine side effects and adjust therapy if needed.

Oral: Infants ≥6 months, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.

Adverse Reactions (Significant): Considerations
CNS effects

Cetirizine may cause CNS depression, including sedated state, drowsiness, and fatigue (Ref). There are rare reports of psychosis and delusion (Ref). In overdose in children, sedation is more likely to occur than with other second-generation antihistamines (Ref).

Mechanism: Dose-related; low brain uptake, binding to ~30% of H1 cerebral receptors (Ref).

Onset: May occur after 1 or 2 doses (Ref). Onset of psychosis has occurred 2 to 7 days after initiation of cetirizine (Ref).

Risk factors:

• Concurrent alcohol use (Ref)

• Older patients (Ref)

• More sedating than other second-generation antihistamines, including loratadine and fexofenadine, but less sedating than first-generation antihistamines such as diphenhydramine (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%: Nervous system: Drowsiness (adolescents and adults: 11% to 14%; children: 2% to 4%) (table 1), headache (children: 14%; adults: <1%)

Cetirizine (Systemic): Adverse Reaction: Drowsiness

Drug (Cetirizine [Systemic])

Placebo

Population

Dose

Number of Patients (Cetirizine [Systemic])

Number of Patients (Placebo)

4%

1%

Children

10 mg

215

309

2%

1%

Children

5 mg

161

309

14%

6%

Adolescents & adults

5 mg or 10 mg

2,034

1,612

14%

6%

Adolescents & adults

10 mg

N/A

N/A

11%

6%

Adolescents & adults

5 mg

N/A

N/A

1% to 10%:

Cardiovascular: Cardiac failure (<2%), chest pain (<2%), edema (<2%), facial edema (<2%), flushing (<2%), hypertension (<2%), lower extremity edema (<2%), palpitations (<2%), peripheral edema (<2%), syncope (<2%), tachycardia (<2%)

Dermatologic: Acne vulgaris (<2%), alopecia (<2%), bullous rash (<2%), cutaneous nodule (<2%), dermatitis (<2%), diaphoresis (<2%), eczema (<2%), erythematous rash (<2%), furunculosis (<2%), hyperkeratosis (<2%), hypertrichosis (<2%), maculopapular rash (<2%), pallor (<2%), pruritus (<2%), seborrhea (<2%), skin photosensitivity (<2%), skin rash (<2%), urticaria (<2%), xeroderma (<2%)

Endocrine & metabolic: Decreased libido (<2%), dehydration (<2%), diabetes mellitus (<2%), heavy menstrual bleeding (<2%), hot flash (<2%), increased thirst (<2%), intermenstrual bleeding (<2%), weight gain (<2%)

Gastrointestinal: Abdominal pain (children: 4% to 6%), ageusia (<2%), anorexia (<2%), aphthous stomatitis (<2%), constipation (<2%), dental caries (<2%), diarrhea (children: 2% to 3%), dysgeusia (<2%), dyspepsia (<2%), enlargement of abdomen (<2%), eructation (<2%), flatulence (<2%), gastritis (<2%), hemorrhoids (<2%), increased appetite (<2%), melena (<2%), nausea (children: 3%), sialorrhea (<2%), stomatitis (<2%), tongue discoloration (<2%), vomiting (children: 2% to 3%), xerostomia (adolescents and adults: 5%)

Genitourinary: Cystitis (<2%), dysmenorrhea (<2%), dysuria (<2%), hematuria (<2%), leukorrhea (<2%), mastalgia (<2%), urinary frequency (<2%), urinary incontinence (<2%), urinary retention (<2%), urinary tract infection (<2%), vaginitis (<2%)

Hematologic & oncologic: Hemophthalmos (<2%), lymphadenopathy (<2%), purpuric disease (<2%), rectal hemorrhage (<2%)

Hepatic: Hepatic insufficiency (<2%)

Hypersensitivity: Angioedema (<2%), tongue edema (<2%)

Nervous system: Abnormality in thinking (<2%), agitation (<2%), altered sense of smell (<2%), amnesia (<2%), anxiety (<2%), ataxia (<2%), confusion (<2%), depersonalization (<2%), depression (<2%), dizziness (adolescents and adults: 2%), emotional lability (<2%), euphoria (<2%), fatigue (4% to 6%) (table 2), hyperesthesia (<2%), hypertonia (<2%), hypoesthesia (<2%), impaired concentration (<2%), insomnia (≤9%), malaise (≤4%), migraine (<2%), myasthenia (<2%), nervousness (<2%), nightmares (<2%), pain (<2%), paralysis (<2%), paresthesia (<2%), rigors (<2%), sleep disorder (<2%), twitching (<2%), vertigo (<2%), voice disorder (<2%)

Cetirizine (Systemic): Adverse Reaction: Fatigue

Drug (Cetirizine [Systemic])

Placebo

Population

Dose

Number of Patients (Cetirizine [Systemic])

Number of Patients (Placebo)

4%

1%

Children

5 mg or 10 mg

N/A

N/A

6%

3%

Adolescents & adults

5 mg or 10 mg

2,034

1,612

Neuromuscular & skeletal: Arthralgia (<2%), arthritis (<2%), asthenia (<2%), back pain (<2%), hyperkinetic muscle activity (<2%), lower limb cramp (<2%), myalgia (<2%), myelitis (<2%), osteoarthrosis (<2%), tremor (<2%)

Ophthalmic: Accommodation disturbance (<2%), blepharoptosis (<2%), blindness (<2%), conjunctivitis (<2%), eye pain (<2%), glaucoma (<2%), periorbital edema (<2%), visual field defect (<2%), xerophthalmia (<2%)

Otic: Deafness (<2%), otalgia (<2%), ototoxicity (<2%), tinnitus (<2%)

Renal: Polyuria (<2%)

Respiratory: Bronchitis (<2%), bronchospasm (children: 3%), dyspnea (<2%), epistaxis (children: 4%), hyperventilation (<2%), increased bronchial secretions (<2%), nasal polyposis (<2%), pharyngitis (2% to 6%), pneumonia (<2%), respiratory system disorder (<2%), rhinitis (<2%), sinusitis (<2%), upper respiratory tract infection (<2%)

Miscellaneous: Fever (<2%)

<1%:

Cardiovascular: Presyncope

Dermatologic: Hyperhidrosis

Nervous system: Feeling hot

Frequency not defined:

Hepatic: Increased serum transaminases (transient, reversible)

Nervous system: Irritability

Miscellaneous: Fussiness in an infant or toddler

Postmarketing:

Cardiovascular: Severe hypotension

Gastrointestinal: Cholestasis (Fong 2000)

Hematologic & oncologic: Hemolytic anemia, thrombocytopenia

Hepatic: Hepatitis (Pompili 2004), increased serum bilirubin

Hypersensitivity: Anaphylaxis (Afonso 2009)

Nervous system: Aggressive behavior, delusion (Garden 2013), hallucination, psychosis (Croitoru 2021), sedated state (Corsico 2019), seizure, suicidal ideation, suicidal tendencies

Neuromuscular & skeletal: Orofacial dyskinesia (Romo 2011)

Renal: Glomerulonephritis

Contraindications

Hypersensitivity to cetirizine, hydroxyzine, levocetirizine, or any component of the formulation.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to piperazine derivatives; severe renal impairment (CrCl <10 mL/minute).

Warnings/Precautions

Concerns related to adverse effects:

• Pruritus: Rebound pruritus has been reported within several days after stopping cetirizine, usually after long-term (eg, months to years) use.

Disease-related concerns:

• Hepatic impairment: Use with caution; consider dosage adjustment.

• Renal impairment: Use with caution; consider dosage adjustment.

Concurrent drug therapy issues:

• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.

Special populations:

• Older adult: Use with caution in elderly patients; may be more sensitive to adverse effects.

Warnings: Additional Pediatric Considerations

Safety and efficacy for the use of cough and cold products in pediatric patients <4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients <2 years of age and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).

Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral, as hydrochloride:

Allergy Relief (Cetirizine): 10 mg

ZyrTEC Allergy: 10 mg

Solution, Intravenous, as hydrochloride [preservative free]:

Quzyttir: 10 mg/mL (1 mL)

Solution, Oral, as hydrochloride:

Allergy Relief Childrens: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]

Cetirizine HCl Allergy Child: 5 mg/5 mL (120 mL) [alcohol free, dye free, gluten free, sugar free; contains methylparaben, propylene glycol, propylparaben; grape flavor]

Cetirizine HCl Allergy Child: 5 mg/5 mL (120 mL) [alcohol free, sugar free; contains methylparaben, propylene glycol, propylparaben; grape flavor]

Cetirizine HCl Allergy Child: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]

Cetirizine HCl Childrens: 5 mg/5 mL (118 mL [DSC]) [contains methylparaben, propylene glycol, propylparaben]

Cetirizine HCl Childrens Alrgy: 5 mg/5 mL (120 mL [DSC]) [contains methylparaben, propylene glycol, propylparaben; grape flavor]

Cetirizine HCl Childrens Alrgy: 5 mg/5 mL (118 mL) [dye free; contains methylparaben, propylene glycol, propylparaben; grape flavor]

Cetirizine HCl Childrens Alrgy: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]

GoodSense All Day Allergy: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]

GoodSense All Day Allergy: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate, sorbitol]

ZyrTEC Childrens Allergy: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate]

ZyrTEC Childrens Allergy: 5 mg/5 mL (30 mL, 118 mL, 236 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]

Generic: 5 mg/5 mL (120 mL, 473 mL, 480 mL)

Tablet, Oral, as hydrochloride:

All Day Allergy: 10 mg [DSC] [contains corn starch]

Allergy (Cetirizine): 10 mg [scored]

Allergy Relief (Cetirizine): 10 mg

Allergy Relief Cetirizine: 5 mg [contains corn starch]

Allergy Relief Cetirizine: 10 mg

Allergy Relief Cetirizine: 10 mg [contains corn starch]

Allergy Relief/Indoor/Outdoor: 10 mg [scored]

GoodSense All Day Allergy: 10 mg [gluten free; contains corn starch, fd&c blue #1 (brill blue) aluminum lake]

ZyrTEC Allergy: 10 mg

Generic: 5 mg, 10 mg

Tablet Chewable, Oral:

ZyrTEC Childrens Allergy: 2.5 mg [dye free; contains corn starch; grape flavor]

Tablet Chewable, Oral, as hydrochloride:

Cetirizine HCl Childrens: 5 mg [DSC], 10 mg [DSC] [contains aspartame, fd&c yellow #6(sunset yellow)alumin lake]

ZyrTEC: 10 mg [dye free; contains corn starch]

ZyrTEC Childrens Allergy: 10 mg [dye free; contains corn starch]

Generic: 5 mg, 10 mg

Tablet Disintegrating, Oral, as hydrochloride:

ZyrTEC Allergy: 10 mg [DSC]

ZyrTEC Allergy Childrens: 10 mg

ZyrTEC Allergy Childrens: 10 mg [citrus flavor]

Generic Equivalent Available: US

May be product dependent

Pricing: US

Capsules (ZyrTEC Allergy Oral)

10 mg (per each): $0.57

Chewable (Cetirizine HCl Oral)

5 mg (per each): $2.47 - $5.36

10 mg (per each): $2.47 - $5.36

Chewable (ZyrTEC Childrens Allergy Oral)

2.5 mg (per each): $0.98

10 mg (per each): $0.85

Chewable (ZyrTEC Oral)

10 mg (per each): $0.85

Solution (Quzyttir Intravenous)

10 mg/mL (per mL): $372.00

Solution (ZyrTEC Childrens Allergy Oral)

1 mg/mL (per mL): $0.10

5 mg/5 mL (per mL): $0.10

Tablet, orally-disintegrating (ZyrTEC Allergy Childrens Oral)

10 mg (per each): $1.00

Tablets (Cetirizine HCl Oral)

5 mg (per each): $2.49 - $2.50

10 mg (per each): $0.05 - $2.50

Tablets (ZyrTEC Allergy Oral)

10 mg (per each): $0.69

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral, as hydrochloride:

Reactine: 20 mg

Generic: 20 mg

Administration: Adult

Oral: May be administered with or without food.

Chewable tablet: Chew tablet before swallowing; may be taken with or without water.

IV: Injection: For IV use only; do not administer IM or SUBQ; administer as an IV push over 1 to 2 minutes.

Administration: Pediatric

Oral: Administer without regard to food.

Chewable tablet: Chew tablet before swallowing; may be taken with or without water.

Dissolving tablet: Allow tablet to melt in mouth; may be taken with or without water.

Liquid: Administer with an accurate measuring device; do not use a household teaspoon (overdosage may occur).

Parenteral: IV: Administer IV undiluted over 1 to 2 minutes; do not administer IM or SubQ.

Use: Labeled Indications

Oral:

Allergic rhinitis: Relief of symptoms associated with allergic rhinitis.

Urticaria, chronic spontaneous: Treatment of uncomplicated skin manifestations of chronic spontaneous urticaria.

Injection:

Urticaria, new onset: Treatment of new-onset (acute) urticaria.

Use: Off-Label: Adult

Anaphylaxis (adjunct to epinephrine for relief of cutaneous symptoms); Angioedema, acute allergic or recurrent idiopathic; Infusion reaction, premedication

Medication Safety Issues
Sound-alike/look-alike issues:

Cetirizine may be confused with sertraline, stavudine

Quzyttir may be confused with Qsymia

ZyrTEC may be confused with Lipitor, Serax, Xanax, Zantac, Zerit, Zocor, ZyPREXA, ZyrTEC-D

International issues:

Benadryl international brand name for cetirizine [Great Britain, Philippines], but also the brand name for acrivastine and pseudoephedrine [Great Britain] and several products containing diphenhydramine [US, Canada]

Metabolism/Transport Effects

Substrate of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. Risk C: Monitor therapy

Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapy

Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents. Risk C: Monitor therapy

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects. Risk D: Consider therapy modification

Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. Risk C: Monitor therapy

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. Risk C: Monitor therapy

Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination

CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider therapy modification

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Risk C: Monitor therapy

DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. Risk X: Avoid combination

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

Gabapentin: Cetirizine (Systemic) may enhance the CNS depressant effect of Gabapentin. Cetirizine (Systemic) may decrease the serum concentration of Gabapentin. Risk C: Monitor therapy

Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor therapy

Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). Risk X: Avoid combination

Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. Risk C: Monitor therapy

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. Risk C: Monitor therapy

Ixabepilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. Risk X: Avoid combination

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Risk C: Monitor therapy

Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor therapy

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use Risk D: Consider therapy modification

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Pilsicainide: May increase the serum concentration of Cetirizine (Systemic). Cetirizine (Systemic) may increase the serum concentration of Pilsicainide. Risk C: Monitor therapy

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. Risk X: Avoid combination

Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid combination

Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid combination

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. Risk X: Avoid combination

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. Risk C: Monitor therapy

Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. Risk X: Avoid combination

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider therapy modification

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. Risk X: Avoid combination

Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Risk C: Monitor therapy

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider therapy modification

Food Interactions

Cetirizine's absorption and maximal concentration are reduced when taken with food. Management: May be taken without regard to meals.

Pregnancy Considerations

Guidelines for the use of antihistamines in the treatment of allergic rhinitis or urticaria in pregnancy are generally the same as in nonpregnant females. Cetirizine may be used when a second generation antihistamine is needed. The lowest effective dose should be used (BSACI [Powell 2015]; BSACI [Scadding 2017]; Zuberbier 2018).

Breastfeeding Considerations

Cetirizine is present in breast milk.

Drowsiness and irritability have been reported in breastfed infants exposed to antihistamines (Ito 1993). In general, second generation antihistamines (eg, cetirizine) are less sedating as compared to their first generation counterparts. If a breastfed infant is exposed to a second generation antihistamine via breast milk, they should be monitored for irritability, jitteriness, or drowsiness (Butler 2014).

When treatment with an antihistamine is needed in breastfeeding women for the treatment of rhinitis or urticaria, a second generation antihistamine, such as cetirizine, is preferred. The lowest effective dose should be used (BSACI [Powell 2015]; BSACI [Scadding 2017]; Butler 2014; Zuberbier 2018).

Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of breastfeeding (Messinis 1985).

Monitoring Parameters

Relief of symptoms, sedation, mental alertness, and anticholinergic effects.

Mechanism of Action

Competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Suppression of skin wheal and flare: Oral: 20 to 60 minutes.

Duration of action: Suppression of skin wheal and flare: Oral: ≥24 hours.

Absorption: Rapid.

Distribution: Children: 0.7 L/kg; Adults: 0.56 L/kg (Simons 1999).

Protein binding, plasma: Mean: 93%.

Metabolism: Limited hepatic.

Half-life elimination: Children: 6.2 hours; Adults: 8 hours.

Time to peak, serum: Oral: 1 hour; IV: 108 seconds.

Excretion: Urine (70%; 50% as unchanged drug); feces (10%).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Cetgel | Cetmax | Cetralon | Finallerg | Gencet | Glotrizine | Omcet | Zeran | Zetop | Zyrtec;
  • (AR) Argentina: Alernix 24 Pediatrico | Alernix 24 rapida accion | Alidial | Atopix | Cabal | Cetizine | Cetriler | Gripaben Aller | Salvalerg | Stopaler | Zyrtec;
  • (AT) Austria: Zirtek | Zyrtec;
  • (AU) Australia: Alzene | Amcal cetirizine | Apo-cetirizine | Chemists own childrens c zine | Little allergies | Pharmacy care cetirizine | Pharmacy choice childrens hayfever & allergy relief | Trust cetirizine | Zyrtec;
  • (BD) Bangladesh: Acetrin | Acitrin | Actizen | Adtrizin | Alarex | Alatin | Alatrol | Allernil | Asitrol | Atrizin | Atrol | Cesil | Cetizin | Cetril | Cetrin | Cezin | Citin | Citrol | Cizin | Ctz | Dyno | Dyzin | Etizin | Histacet | Moset | Noler | Nosemin | Ontin | Orgy | Procet | Rhinil | Riz | Rizin | Sartec | Silatrol | Tiz | Trin | Trizin | Tytrol | Zervin | Zinal | Zyrtec;
  • (BE) Belgium: Cetirizine Bexal | Cetirizine eurogenerics | Cetirizine teva generics belgium | Cetisandoz | Zyrtec;
  • (BF) Burkina Faso: Alerid | Allertin | Ceticad | Cetix | Curtec | Zyrtec;
  • (BG) Bulgaria: Allersan | Cetiristad | Egirizin | Reactin | Talert | Zodac | Zyrtec;
  • (BR) Brazil: Alersin | Aletir | Cetirtec | Cetrizin | Dicloridrato de cetirizina | Reactine | Zetalerg | Zetir | Zyrtec;
  • (CH) Switzerland: Cerzin | Cerzin mepha | Cetallerg | Cetallerg sandoz | Cetirizin mepha | Cetirizin Streuli | Cetirizine helvepharm | Zyrtec;
  • (CI) Côte d'Ivoire: Airlix | Alerid | Allercet | Ceticad | Cezin | Curtec | Genset | Rinacet | Roncet | Zetry mepha | Zyncet | Zyrtec;
  • (CL) Chile: Alertop | Cetialer | Findaler | Histalen | Histax | Nonaler | Remitex | Rigotax | Sanaler | Zyrtec;
  • (CN) China: An di xi si | Ao bo da | Bei fen | Bi te li | Cetirizine | Cetirizine dihydrochloride | Cetrizet | Di di | Jie jie | Lu cheng | Sheng min qing | Shi di | Shuang te | Wei Di Min | Xi ke wei | Xi Li | Xi ning | Xi te rui | Xi wa ding | Xue ding | Yi meng | Yi Wei Tuo | Ying xin mei shu | Zinit | Zyrtec;
  • (CO) Colombia: Acidrine | Alercet | Alerfrin | Alergex | Alerviden | Allerzitina | Allerzitina kids | Birtex | Bonarazina | Ceriz t | Cetirax | Cetirizina | Cetirizina Ecar | Cetirizina MK | Cetirizina WINTHROP | Cetirrinol | Cetrine | Expotizina | Histarizina | Mega we care zirin | Nivox | Optiser | Rincetir | Xetrix | Zeridal | Zeridil | Zyrfar | Zyrtec;
  • (CZ) Czech Republic: Alerid | Letizen | Zodac | Zyrtec;
  • (DE) Germany: Cetirizin | Cetirizin 1a pharma | Cetirizin al | Cetirizin aristo | Cetirizin beta | Cetirizin hexal | Cetirizin sandoz | Cetirizin stada | Cetirizin zum einnehmen | Cetirizin-ratiopharm | Docmorris Cetirizin | Zyrtec;
  • (DK) Denmark: Benaday;
  • (DO) Dominican Republic: Abravia | Alercet | Alerfrin | Alernadina | Alerviden | Amazina | Cetir | Cetirax | Cetirina | Cetirizina | Cetirizina Inmenol | Cetirizina lam | Cetirizina mamey | Cetirizina MK | Cetizin | Cliartek | Histal | Interant | Kalven | Luterizina | N Cistil | Sinalerg | Talerdin | Tirizin | Zetri | Zinaltec | Zyrtec;
  • (EC) Ecuador: Alercet | Alerpasol | Amazina | Cetirizina | Cetirizina la sante | Cetrine | Ciritex | Cotalil | Flufin allergy | Histax | Respixion | Rhinodina | Rigotax | Talerdin | Tolmex | Zyrtec;
  • (EE) Estonia: Aceterin | Aceterin express | Cetrix | Letizen | Reactin | Zyrtec;
  • (EG) Egypt: Alerid | Cetirizine | Cetrak | Cetrichew | Cetritin | Epirizine | Histazine | Histazine 1 | Lergfree | Tomazine | Zyrtec;
  • (ES) Spain: Alerlisin | Cetirizina cipla | Cetirizina Ranbaxy | Cetirizina Sandoz | Garpon | Ratioalerg | Reactine | Virlix | Zyrtec;
  • (ET) Ethiopia: Arcet | Cetirizine dihydrochloride | Finallerg | Zyncet;
  • (FI) Finland: Cetirizin sandoz | Cetirizin-ratiopharm | Heinix | Senirex | Zyrtec;
  • (FR) France: Alairgix | ALAIRGIX ALLERGIE | Cetirizine Biogaran | Cetirizine EG | Virlix | Zyrtec;
  • (GB) United Kingdom: Allergy & Hayfever Relief | AllerTek | Benadryl allergy | Benadryl for Children Allergy Solution | Benadryl one a day relief | Cetirizine | Cetirizine Kent | Cetirizine sandoz | Galpharm hayfever | Hayfever & allergy relief | Hayfever and Allergy Relief | Hayfever relief | Numark Allergy Relief for Children | Piriteze | T&r hay fever | Wockhardt Allergy and Hayfever Relief | Ziralton | Zirtek;
  • (GR) Greece: Alenstran | Dermizin | Zepholin | Zirtek;
  • (HK) Hong Kong: Adezio | Alesof | Allutec | Altirin | Apo-cetirizine | Avotec | Cerotec | Cetec | Cetia | Cetihis | Cetirin | Cetirizin | Cetirizine | Cetirizine dihydrochloride | Cetisin | Cetzie | Citriza | Cytec | Jmp cetirizine | Laricetin | Letizen | Mantab | Pharmaniaga cetirizine | Rizine | Simtec | Sunizine | Terizine | Tirizine | Uni-Certec | Vick Zyrt | Vidatec | Zetizine | Zicet | Zymed | Zyrtec;
  • (HU) Hungary: Cetrin Akut | Cetrizin hexal | Parlazin | Zyrtec;
  • (ID) Indonesia: Betarhin | Capritazin | Cerini | Cetaler | Cetinal | Cetirgi | Cetirizine | Cetirizine HCL | Cetryn | Cetymin | Falergi | Histrine | Incidal-od | Intrizin | Lerzin | Nichorizin | Omezyrteks | Ozen | Rinocet | Risina | Ritez | Rozine | Rydian | Ryvel | Ryzen | Simzen | Tiriz | Yarizine | Zenriz;
  • (IE) Ireland: Anti hist allergy | Cetrine allergy | Histek | Tiritek allergy | Zirtek | Zynor;
  • (IL) Israel: Allergy Care | Histazine;
  • (IN) India: Acet | Agicet | Airtis | Alce | Alcet | Alday | Alego | Alerbloc | Alerid | Alertac | Allercet | Allerzine | Allicet | Alocet | Alzine | Ancet | Anzin | Atozine | Atzine | Aurocitin | Batriz | Bealert | Bio act | C zen | Cerizine | Cerzin | Cet | Cetag | Cetariv | Cetcip | Ceten | Ceterezol | Cetfast | Cetgel | Ceti | Ceticad | Cetiminic | Cetin | Cetinam | Cetipen | Cetiriz | Cetirizine | Cetirizine di-hcl | Cetiz | Cetoz | Cetral | Cetramac | Cetrezol | Cetri | Cetride | Cetrifil | Cetrimark | Cetrimol | Cetrina md | Cetrinat | Cetrine | Cetritab | Cetritop | Cetriwin | Cetrizet | Cetrizine | Cetzine | Cez | Cezin | Cistin | Citimed | Citirizine | Citla | Citol | Citrazan | Citri a | Cope | Coszin | Ctz | Ctzine | Cypzine | Cz-3 | Dio-1 | Ekon | Epocrin | Floramin | Fomicet | Hicet | Hisnofil | Histacet | Histazin | Holday | Inalam | Incid-l | Intazin | Lgnil | Locet | Lodizin | Lupicet | Lycet | M-cet | M-triz | Mast 1 | Mdzime | Morazin | Neusonil | Odacet | Okacet | Oncet | One-a-day | Opticet | Ozocin | Percet | Rhinocet | Rhizin | Rincet | Satrin | Setimed | Setride | Sizon | Stanhist | Supres | Suzicet | Tancet | Triz | Trizin | Unicet | Zene | Zimat | Zine | Zircet | Zirtin | Zolase | Zolong | Zyncet | Zyrtec;
  • (IT) Italy: Axeramis | Ceteris | Cetirizina actavis | Cetirizina Doc | Cetirizina eg | Cetirizina Fg | Cetirizina Myl | Cetirizina pensa | Cetirizina Ranbaxy | Cetirizina teva | Formistin | Kruzin | Leviorinil | Prizitec | Raingen | Rinalgit | Ritecam | Sotrizol | Suspiria | Tezastin | Virlix | Zirtec;
  • (JO) Jordan: Allezine | Cerin | Cetolerg | Finallerg | Omcet | Siraz | Zertazine | Zyretic | Zyrtec;
  • (JP) Japan: Contac z | Stona rhini z;
  • (KE) Kenya: Acitrin | Actizine | Adco-cetirizine | Alatrol | Alerid | Alfree | Altrine | Alzinex | Arcet | Ascet | Atrizex | Atrizin | Cachcet | Ceticad | Cetmax | Cetramac | Cetriz | Cezine | Copazine | Curtec | Finallerg | Grazine | Rinacet | Ronex;
  • (KR) Korea, Republic of: Albitec | Algyssak ceti | Allercap | Alleren | Allerina | Allershot | Allertec | Alligin | Artec | Arucool | Cenova | Cenova quick | Cerazine | Ceritec | Ceritin | Cetirin | Cetirizine | Cetizine | Cetran | Cetrin | Cirozeno | Conazine a | Florizine | Hulerzine | Jurtec | Kizine | Laricetin | Lergystop | Rizine | Rogitec | Rzn speed | Senoba | Seritex | Serote | Serotec | Srtec | Tallerzi | Tirazen | Ziset | Zyrtec;
  • (KW) Kuwait: Alerid | Cetralon | Glotrizine | Omcet | Rinalgit | Zertazine | Zyrtec;
  • (LB) Lebanon: Cetimed | Cetrak | Finallerg | Micet | Rinalgit | Zyrtec;
  • (LT) Lithuania: Aceterin | Cetirizine | Zyrtec;
  • (LU) Luxembourg: Zyrtec;
  • (LV) Latvia: Cetirizine | Cetrix | Reactin | Zyrtec;
  • (MA) Morocco: Airlix | Aler z | Atopix | Cetiral | Cezin | Curtec | Virlix | Zadryl | Zyrtec;
  • (MX) Mexico: Apoliz | Cethexal | Cetirizina | Cetirizina gi serr | Degortzin | Dercetina | Hizidro | Indelin | Kenicet | Miseda | Raamcinet | Retirix | Tradaxin | Virlix | Visertral | Zinobru | Zyrtec;
  • (MY) Malaysia: Adezio | Alatrol | Allerzine | Axcel cetirizine | Ceritec | Cetazine | Cetihis | Cetirizine | Cetirizine b | Cetiz | Cetrizet | Cetrizin | Histasin | Intazin | Ricam | Simtec | Stanhist | Sunizine | Triz | Urtirizine | Xetec | Zertin | Zicet | Zirin | Zyrtec;
  • (NG) Nigeria: Atribex | Atribex pediatric drops | Axcel cetririzine | Cetidyn | Jawazine | Sterizine | Viscetrin | Zyncet;
  • (NL) Netherlands: Cetirizine 2 HCl Medcor | Cetirizine 2HCl PCH | Cetirizine dihcl | Cetirizine diHCl A | Cetirizine Dihcl CF | Reactine | Revalintabs | San cetiriz.dihcl | Zyrtec;
  • (NO) Norway: Acura | Alzyr | Cetirizin | Cetirizin bmm pharma | Cetirizin sandoz | Reactine | Zyrtec;
  • (NZ) New Zealand: Aft Cetirizine | Allerid c | Apo cetirizine | Apo-cetirizine | Histaclear | Pharmacy health cetirizine hayfever & allergy relief | Razene | Zetop | Zyrtec;
  • (OM) Oman: Omcet;
  • (PE) Peru: Alercet | Alercheck plus | Alerdif | Alerfree c | Alergizina | Alermizol nf | Alerplax | Alertop | Alerxal | Alerzin | Alexmin | Alleghysina | Allercom | Allergizer | Amazina | Antialer | Asint | Cethystan | Cetirizina | Cetirizina fmndtria | Cetirizina mf | Cetrikem | Cetrixin | Dulergina | Findaler | Flexmed | Hisaler | Histalen | Hizalab | Lergium | Noalergyn | Pharmaler | Rigotax | Rinacet | Tdn Allergy | Tirizin allergy | Xeniler | Zetaler | Zetix | Zyncet | Zyrtec;
  • (PH) Philippines: Aforvir | Alerex | Alergone | Alerid | Aletor | Alfree | Allecur | Allecur P | Allercef | Allerkid | Allermed | Alnix | Antrazine | Askey | Avec | Axella | Boie cetirizine | Cerotec | Ceti med | Cetirizine | Cetizin | Cetrigna | Cetzet | Cetzy | Dintec | Ezaller | H One | H-One | Histamed | Medan | Medrizine | Prixlae | Qualcet | Reax | Rhinicet | Rhinitrin | Ricam | Ritemed cetirizine | Saphzine | Selergy | Sitizine | Temprazin | Trizin | Unizef | Virlix | Virtec | Welcet | Zericin | Zerlex | Zetir | Zetrix | Zinex | Zyriz | Zyrrigin | Zyrtec;
  • (PK) Pakistan: Al tak | Alce | Alcit | Alegra | Alergicare | Alergo | Alerid | Alex | Algezen | Allamine | Aller tec | Allergid | Allos | Alzine | Apozine | Arex | Arix | Arozine | Atcet | Avazine | Avec | Azorine | Bytec | Cekim | Cenex | Ceridal | Cerizine | Cetariv | Cetfast | Cetfold | Cetorid | Cetrido | Cetrihit s | Cetrin | Cetrine | Cetrix | Cetroflash | Cezine | Cipzin | Cistazine | Citpharm | Citraclor | Citragic | Citrazit | Citresal | Citrisaf | Ctzine | Czet | Davizin | Deebar | Dopnil | Egix | Fastec | Firax | Gixer | Histex | Hozin | Incidal-neo | Instazin | Inzee | Kanzeen | Lgnil | Linazine | Neset | No-all | Nostamin | Rakzine | Rex | Rhizin | Rigix | Rizox | Ronex | Rozen | Sedil | Selzine | Sn zyr | Stamin | Tirix | Trezine | Trine | Xero sed | Z-Tek | Zanlan | Zecit | Zetrine | Zilcit | Zine | Zineva | Zyrtec | Zysic;
  • (PL) Poland: Allertec | Amertil | Cetalergin | Cetyryzyna egis | Zyrtec;
  • (PR) Puerto Rico: All Day Allergy | Cetirizine | Cetirizine HCL | Children's Cetirizine hydrochloride | Children's Zyrtec | Children's zyrtec allergy | Children's Zyrtec hives relief | Childrens allergy relief | Quzyttir | Zerviate | Zyrtec | Zyrtec allergy | Zyrtec Hives Relief;
  • (PT) Portugal: Cetix | Virlix | Zyrtec;
  • (PY) Paraguay: Alergina | Alertop | Antistam | Cerizina | Cetirizina bilac | Cetrizet | Galetrix | Terizin;
  • (RO) Romania: Cetrine | Reactin | Zyrtec;
  • (RU) Russian Federation: Cetirizin | Cetirizin hexal | Cetirizine | Cetrine | Letizen | Parlazin | Solonex | Zetrinal | Zodac | Zyncet | Zyrtec;
  • (SA) Saudi Arabia: Cetralon | Citrin | Finallerg | Glotrizine | Nohist | Omcet | Rizino | Zertazine | Zyrtec;
  • (SE) Sweden: Acura | Cetirizin sandoz | Zyrlex;
  • (SG) Singapore: Adezio | Alzytec | Ceritec | Cetrine | Rhizin | Rizine | Sunizine | Zicet | Zyrtec | Zyrtec r;
  • (SI) Slovenia: Letizen | Reactin | Zyrtek;
  • (SK) Slovakia: Cetirizin | Parlazin | Zodac | Zyrtec;
  • (TH) Thailand: Aller Go | Celatag | Cetab | Cetihis | Cetrizin | Cettec | Ceza | Cistamine | Cyzine | Histec | Histica | Incidal-od | Mantab | Nytec | One-trex | Ormist | P zine | Pipnaso | Rhitecin | Setin | Tizine | Triz | Utizine | Zaridec | Zensil | Zermed | Zertine | Zetecine | Zetrix | Zittec | Zydon | Zymed | Zyral | Zyrex | Zyrrizin | Zyrrizine | Zyrtec | Zytine | Zytizine;
  • (TN) Tunisia: Allergica | Allertec | Arhin | Cetolerge | Zyrtec;
  • (TR) Turkey: Allerset | Cetiteva | Cetryn | Hitrizin | Lergy | Rynset | Setir | Yenizin | Zyrtec;
  • (TW) Taiwan: Alltec | Cetia | Cetirizine | Minergy | Nonsed | Tirizin | Zocomin | Zyrtec;
  • (UA) Ukraine: Allertec | Cetirizine | Cetrin | Rolinoz | Zyrtec;
  • (UG) Uganda: Actizine | Alerid | Altrine | Arcet | Ascet | Axcel cetirizine | Cachet | Centrozine | Cetrak | Cetramac | Cetriren | Cezin | Finallerg | Oncet | Stamin | Welbeen | Zyncet;
  • (UY) Uruguay: Cetirizina Regueiro;
  • (VE) Venezuela, Bolivarian Republic of: Acitrin | Alatrol | Celay | Cetirina | Cetirivax | Cetirizina | Cetirizina (cetirex) | Cetral | Cetrine | Cetriz | Cliartek | Talerc | Talzic | Virlix | Zyrtec;
  • (VN) Viet Nam: Bluecezin | Kacerin | Lergitec;
  • (ZA) South Africa: Acuzyrt | Allecet | Allesoothe | Aspen cetirizine | Ceticit | Cetirizine hexal | Gulf cetirizine | Sinutab sinus allergy | Texa | Trantrin | Ucb cetirizine | Zelary | Zetop | Zinallerg | Zyrtec;
  • (ZM) Zambia: Alatrol | Alerid | Altrine | Cetirizin | Cetirizine | Cetirizine hexal | Cetri | Eze dt | Oncet | Rinacet | Sheltrizine | Texa | Triz | Tryzin | Zimat | Zyncet;
  • (ZW) Zimbabwe: Histacet
  1. Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med. 1997;157(5):494-500. [PubMed 9066452]
  2. Afonso N, Shetgaonkar P, Dang A, Rataboli PV. Cetirizine-induced anaphylaxis: a rare adverse drug reaction. Br J Clin Pharmacol. 2009;67(5):577-578. doi:10.1111/j.1365-2125.2009.03394.x [PubMed 19552754]
  3. American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. Available at http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/.
  4. American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  5. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 169.
  6. Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 19, 2021.
  7. Awni WM, Yeh J, Halstenson CE, Opsahl JA, Chung M, Matzke GR. Effect of haemodialysis on the pharmacokinetics of cetirizine. Eur J Clin Pharmacol. 1990;38(1):67-69. doi:10.1007/BF00314806 [PubMed 1970299]
  8. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70(3):417. doi: 10.1016/j.jaad.2013.09.009. [PubMed 24528912]
  9. Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45(1):101. doi: 10.1186/s13052-019-0695-x. [PubMed 31416456]
  10. Campbell RL, Kelso JM. Anaphylaxis: emergency treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 25, 2021.
  11. Castells MC, Matulonis UA, Horton TM. Infusion reactions to systemic chemotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2020.
  12. Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. MMWR Morb Mortal Wkly Rep. 2007;56(1):1-4. [PubMed 17218934]
  13. Cetirizine hydrochloride oral solution [prescribing information]. Berlin, CT: Breckenridge Pharmaceutical; April 2020.
  14. Cetirizine tablet [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; February 2012.
  15. Cheng A. Emergency treatment of anaphylaxis in infants and children. Paediatr Child Health. 2011;16(1):35-40. [PubMed 22211074]
  16. Cicardi M, Aberer W, Banerji A et al; HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602-616. doi: 10.1111/all.12380. [PubMed 24673465]
  17. Corsico AG, Leonardi S, Licari A, et al. Focus on the cetirizine use in clinical practice: a reappraisal 30 years later. Multidiscip Respir Med. 2019;14:40. doi:10.1186/s40248-019-0203-6 [PubMed 31827796]
  18. Croitoru D, Brooks SG, Piguet V, MacGillivray L. Cetirizine-induced psychosis in a young adult with erythema multiforme. BMJ Case Rep. 2021;14(2):e241393. doi:10.1136/bcr-2020-241393 [PubMed 33547112]
  19. Del Pozzo-Magaña B. Chronic Urticaria in Children: A Review. EMJ Dermatol. 2017;5(1):74-82.
  20. deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2020.
  21. Durham CG, Thotakura D, Sager L, Foster J, Herrington JD. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions [published online ahead of print November 12, 2018]. J Oncol Pharm Pract. doi: 10.1177/1078155218811505. [PubMed 30419768]
  22. Estelle F, Simons R. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol. 1999;83(5):481-488. doi:10.1016/s1081-1206(10)62855-4 [PubMed 10582735]
  23. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  24. Fong DG, Angulo P, Burgart LJ, Lindor KD. Cetirizine-induce cholestasis. J Clin Gastroenterol. 2000;31(3):250-253. doi:10.1097/00004836-200010000-00016 [PubMed 11034010]
  25. Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. Available at https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm. Last accessed November 2, 2018.
  26. Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. Available at https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm. Last accessed November 2, 2018.
  27. Garden BC, Francois D. Cetirizine-associated delusions and depression in an 18-year-old woman. Clin Neuropharmacol. 2013;36(3):96-97. doi:10.1097/WNF.0b013e318290b9b2 [PubMed 23673913]
  28. Horak F, Stübner UP. Comparative tolerability of second generation antihistamines. Drug Saf. 1999;20(5):385-401. doi:10.2165/00002018-199920050-00001 [PubMed 10348091]
  29. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168(5):1393-1399. [PubMed 8498418]
  30. James C, Bernstein JA. Current and future therapies for the treatment of histamine-induced angioedema. Expert Opin Pharmacother. 2017;18(3):253-262. doi: 10.1080/14656566.2017.1282461. [PubMed 28081650]
  31. Khan DA. Chronic spontaneous urticaria: Standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 24, 2021.
  32. Kirkham B. Tumor necrosis factor-alpha inhibitors: An overview of adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 2, 2021.
  33. Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019. [PubMed 26505932]
  34. Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000;320(7243):1184-1186. doi:10.1136/bmj.320.7243.1184 [PubMed 10784544]
  35. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;97(2):617-626. doi:10.1016/s0091-6749(96)70307-x [PubMed 8621847]
  36. Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Invest. 1985;8(2):143-146. [PubMed 3928731]
  37. Ng KH, Chong D, Wong CK, et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. Pediatrics. 2004;113(2):e116-e121. doi:10.1542/peds.113.2.e116 [PubMed 14754980]
  38. Noiri E, Ozawa H, Fujita T, Nakao A. Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. Nephron. 2001;89(1):101-104. doi:10.1159/000046050 [PubMed 11528239]
  39. Pompili M, Basso M, Grieco A, Vecchio FM, Gasbarrini G, Rapaccini GL. Recurrent acute hepatitis associated with use of cetirizine. Ann Pharmacother. 2004;38(11):1844-1847. doi:10.1345/aph.1E162 [PubMed 15383643]
  40. Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-565. doi: 10.1111/cea.12494. [PubMed 25711134]
  41. Quzyttir (cetirizine) [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; March 2020.
  42. Reactine (cetirizine) [product monograph]. Markham, Canada: McNeil Consumer Healthcare; March 2021.
  43. Reactine 20 mg Tablet (cetirizine) [product monograph]. Markham, Canada: McNeil Consumer Healthcare; March 2021.
  44. Romo CA, Joshi KG, Waters BM. Involuntary movements associated with cetirizine use. Am J Psychiatry. 2011;168(8):855. doi:10.1176/appi.ajp.2011.11040534 [PubMed 21813500]
  45. Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007). Clin Exp Allergy. 2017;47(7):856-889. [PubMed 30239057]
  46. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  47. Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2007;62(8):830-837. doi: 10.1111/j.1398-9995.2007.01435.x. [PubMed 17620060]
  48. Simons FE, Ardusso LR, Bilò MB, et al; World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. 2011;127(3):587-593.e1-22. doi: 10.1016/j.jaci.2011.01.038. [PubMed 21377030]
  49. Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2015;8(1):32. doi: 10.1186/s40413-015-0080-1. [PubMed 26525001]
  50. Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999;36(5):329-352. [PubMed 10384858]
  51. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. doi: 10.1111/all.13397. [PubMed 29336054]
  52. Zuraw B. An overview of angioedema: Clinical features, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 22, 2019.
  53. Zyrtec Allergy (cetirizine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare; received May 2023.
  54. Zyrtec (cetirizine hydrochloride) [prescribing information]. New York City, NY: Pfizer Labs; May 2006.
Topic 113446 Version 541.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟